Cefepime–Zidebactam for Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria, Including Metallo-β-Lactamase Producers: A Phase 2, Open-Label, Single-Arm, Multicenter Study

Clicks: 34
ID: 333717
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #445 of 659 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 659 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Background Infections caused by carbapenem-resistant (CR) Gram-negative bacteria, particularly metallo-β-lactamase (MBL)-producers, have limited treatment options. Cefepime–zidebactam retains activity against these pathogens, but clinical data are limited. Methods This prospective, open-label, single-arm, multicenter phase 2 trial enrolled adults with CR Gram-negative infections. Participants received intravenous cefepime–zidebactam for 7–21 days with renal dose adjustment. The Micro-ITT population included participants with a confirmed qualifying CR Gram-negative pathogen, and the CME population included those meeting prespecified evaluability criteria. The primary endpoint was investigator-assessed clinical cure at TOC in the CME population. Outcomes were also reviewed by an external adjudication committee. Results Seventy-two participants received treatment; 68 were included in the Micro-ITT population and 60 in the CME population. Among 68 qualifying isolates, 56 (82.4%) were MBL producers, predominantly NDM-β-lactamase producers. Investigator-assessed clinical cure at test-of-cure in the CME population was 91.7% (95% confidence interval, 81.6%–97.2%), and favorable microbiological outcome at TOC was 90.0%. Among participants in the CME population with MBL-producing pathogens, clinical cure was 93.9% and favorable microbiological outcome was 91.8%. External adjudication in the CME population yielded clinical cure of 86.7% and favorable microbiological outcome of 85.0%. Twenty-eight-day mortality was 2.8%. Treatment-related adverse events occurred in 15.3%, and serious treatment-related adverse events occurred in 2.8%. Conclusions In 60 evaluable adults with carbapenem-resistant Gram-negative infections, predominantly MBL-producing (81.7%) and cUTI/AP (58.3%), investigator-assessed TOC clinical cure was 91.7%; post hoc adjudicated cure was 86.7%. Day 28 all-cause mortality was 2.8%, and cefepime zidebactam was well tolerated.
Reference Key
openalex_W7223277161 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag665
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.